Trials / Terminated
TerminatedNCT02936037
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 642 (actual)
- Sponsor
- MedDay Pharmaceuticals SA · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MD1003 100mg capsule | |
| DRUG | PLACEBO | an inactive substance |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2019-11-15
- Completion
- 2020-04-23
- First posted
- 2016-10-18
- Last updated
- 2020-11-23
- Results posted
- 2020-11-23
Locations
92 sites across 13 countries: United States, Australia, Belgium, Canada, Czechia, Germany, Hungary, Italy, Poland, Spain, Sweden, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT02936037. Inclusion in this directory is not an endorsement.